Approval of COVID19-study

Maastricht University Hospital receives approvals to start study with Annexin Pharmaceuticals drug candidate, ANXV, in patients with COVID19.STOCKHOLM, SWEDEN (January 19, 2022) – Annexin Pharmaceuticals AB (publ) announces that its collaborators at Maastricht University Hospital, Maastricht, The Netherlands, have received approvals from the Dutch regulatory authority and Hospital committees to start a trial with ANXV (a recombinant human Annexin A5) in hospitalised COVID-19 patients. The study follows upon Annexin Pharmaceutical’s completed Phase 1 trial of ANXV in healthy volunteers.